Ilkka Oyj financials
Ilkka Oyj
743700KMZL7E8PLI5X73 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €37.8M | €30.8M |
| Other income | €2.3M | €2.6M |
| Employee benefits expense | €22.8M | €21.1M |
| Operating profit (EBIT) | -€1.1M | -€2.9M |
| Net finance income / (cost) | €5.1M | €7.3M |
| Profit before tax | €4.1M | €4.3M |
| Income tax expense | €186.0K | -€273.0K |
| Profit for the year | €11.6M | €6.2M |
| — attributable to owners | €11.6M | €6.2M |
| Total comprehensive income | €41.9M | €18.7M |
| Per share | ||
| Basic EPS | €0.46 | €0.24 |
| Diluted EPS | €0.46 | €0.24 |
| Free cash flow / share | €0.24 | €0.10 |
| Cash flow statement | ||
| Cash generated from operations | €7.4M | €240.0K |
| Net cash from operating activities | €7.7M | €3.8M |
| Net cash from investing activities | -€226.0K | -€14.5M |
| Net cash from financing activities | -€6.5M | €3.0M |
| Dividends paid | €5.6M | €5.1M |
| Lease liability payments | €315.0K | €363.0K |
| Net change in cash | €958.0K | -€7.7M |
| Balance sheet | ||
| Total assets | €231.9M | €200.1M |
| Non-current assets | €202.2M | €171.8M |
| Right-of-use assets | €1.4M | €676.0K |
| Intangible assets & goodwill | €33.7M | €34.5M |
| Current assets | €29.7M | €28.3M |
| Trade & other receivables | €4.9M | €5.8M |
| Cash & equivalents | €9.9M | €8.9M |
| Total equity | €206.0M | €169.7M |
| Non-current liabilities | €13.6M | €4.9M |
| Long-term borrowings | €8.5M | €72.0K |
| Lease liabilities (non-current) | €949.0K | €351.0K |
| Current liabilities | €12.3M | €25.5M |
| Short-term borrowings | €1.0M | €10.0M |
| Lease liabilities (current) | €631.0K | €341.0K |
| Trade & other payables | €8.2M | €10.0M |
| Deferred tax liabilities | €4.0M | €4.4M |
| Derived metrics | ||
| Free cash flow | €6.1M | €2.6M |
| Operating margin | -2.9% | -9.5% |
| Net margin | 30.8% | 20.1% |
| Return on equity | 5.6% | 3.6% |
| Cash conversion ratio | 0.66× | 0.61× |
| Capex coverage | 4.85× | 3.24× |
| Other reported items | ||
| Adjusted Weighted Average Shares | 25.4M | 25.4M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€734.0K | €1.8M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €5.2M | €4.2M |
| Adjustments For Fair Value Gains Losses | -€1.2M | -€1.1M |
| Adjustments For Finance Income Cost | €3.9M | €6.2M |
| Adjustments For Income Tax Expense | €325.0K | -€233.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | €3.3M | -€4.2M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€7.1M | -€121.0K |
| Adjustments For Undistributed Profits of Associates | €106.0K | €221.0K |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | -€6.7M | -€3.6M |
| Basic Earnings Loss Per Share From Continuing Operations | €0.15 | €0.18 |
| Basic Earnings Loss Per Share From Discontinued Operations | €0.31 | €0.06 |
| Cash Flows From Used In Decrease Increase In Shortterm Deposits and Investments | -€12.0K | €9.5M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €27.5M |
| Comprehensive Income Attributable To Owners of Parent | €41.9M | €18.7M |
| Current Advances | €2.4M | €5.1M |
| Current Tax Assets Current | €0 | €8.0K |
| Current Tax Liabilities Current | €128.0K | €130.0K |
| Deferred Tax Assets | €799.0K | €1.2M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €5.2M | €3.8M |
| Diluted Earnings Loss Per Share From Continuing Operations | €0.15 | €0.18 |
| Diluted Earnings Loss Per Share From Discontinued Operations | €0.31 | €0.06 |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.25 | — |
| Dividends Received Classified As Investing Activities | €4.1M | €4.1M |
| Dividends Received Classified As Operating Activities | €549.0K | €425.0K |
| Dividends Recognised As Distributions To Owners Per Share | €0.22 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €44.0K | €0 |
| Equity and Liabilities | €231.9M | €200.1M |
| Income Taxes Paid Refund Classified As Operating Activities | €61.0K | €237.0K |
| Increase Decrease In Working Capital | -€2.6M | €2.4M |
| Increase Decrease Through Transfers and Other Changes Equity | — | -€117.0K |
| Intangible Assets Other Than Goodwill | €19.8M | €23.0M |
| Interest Paid Classified As Operating Activities | €449.0K | €81.0K |
| Interest Received Classified As Operating Activities | €166.0K | €752.0K |
| Investment Property | €2.4M | €553.0K |
| Investments In Associates Accounted For Using Equity Method | €11.6M | €7.1M |
| Issued Capital | €6.4M | €6.4M |
| Noncurrent Financial Assets Measured At Fair Value Through Other Comprehensive Income | €130.2M | €100.1M |
| Noncurrent Payables | €132.0K | €84.0K |
| Noncurrent Receivables | €944.0K | €924.0K |
| Other Adjustments To Reconcile Profit Loss | -€1.0K | €126.0K |
| Other Comprehensive Income | €30.2M | €12.5M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €149.0K | -€95.0K |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | €30.1M | €12.6M |
| Other Current Financial Assets | €14.9M | €13.7M |
| Other Expense By Nature | €8.5M | €8.7M |
| Other Inflows Outflows of Cash Classified As Operating Activities | €4.0K | €2.7M |
| Payments To Acquire Or Redeem Entitys Shares | €0 | €0 |
| Proceeds From Current Borrowings | €0 | €10.0M |
| Proceeds From Disposal of Noncurrent Assets Or Disposal Groups Classified As Held For Sale and Discontinued Operations | -€7.0M | €478.0K |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €38.0K | €298.0K |
| Proceeds From Noncurrent Borrowings | €10.0M | €0 |
| Proceeds From Sales of Interests In Associates | €4.6M | €28.0K |
| Profit Loss From Continuing Operations | €3.9M | €4.6M |
| Profit Loss From Discontinued Operations | €7.8M | €1.6M |
| Purchase of Financial Assets Measured At Fair Value Through Other Comprehensive Income Classified As Investing Activities | €1.0K | €16.0K |
| Purchase of Interests In Associates | €454.0K | €209.0K |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €1.6M | €1.2M |
| Repayments of Current Borrowings | €10.0M | €1.6M |
| Repayments of Noncurrent Borrowings | €572.0K | €0 |
| Reserve of Exchange Differences On Translation | -€275.0K | -€425.0K |
| Reserve of Gains and Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income | €73.1M | €43.0M |
| Retained Earnings | €78.6M | €72.5M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | €106.0K | €221.0K |
| Treasury Shares | €357.0K | €357.0K |
| Weighted Average Shares | 25.4M | 25.4M |
Every line item above is a fact tagged in Ilkka Oyj's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.